- Molecular NameCapecitabine
- Synonymcapecitabine; R340
- Weight359.354
- Drugbank_IDDB01101
- ACS_NO154361-50-9
- Show 2D model
- LogP (experiment)0.043
- LogP (predicted, AB/LogP v2.0)0.03
- pkaN/A
- LogD (pH=7, predicted)0.03
- Solubility (experiment)26 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.75
- LogSw (predicted, AB/LogsW2.0)1.24
- Sw (mg/ml) (predicted, ACD/Labs)0.29
- No.of HBond Donors3
- No.of HBond Acceptors9
- No.of Rotatable Bonds7
- TPSA120.69
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Absorption_value96.0
- Absorption (description)Capecitabine is extensively absorbed after oral administration
- Caco_2N/A
- Bioavailability100.0
- Protein binding60.0
- Volume of distribution (VD)270 l/m2
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHydrolysed first to 5′-deoxy-5-fluorocytidine (5′-DFCR) by a carboxylesterase. 5′-DFCR is then converted to 5′-deoxy-5-fluorouridine (5′-DFUR) by cytadine deaminase to 5′-fluorouracil by thymidine phosphorylase to 5-fluoro-5,6-dihydrofluorouracil (FUH2) to 5-fluoro-ureidopropionic acid (FUPA) and to α-fluoro-β-alanine (FBAL) by β-ureidopropionase.
- Half life1.3 h
- ExcretionMore than 95% of an administered dose is excreted in urine, with approx. 3% unchanged and 5% as FBAL, the major metabolite. 2.5% of the dose is recovered in faeces.
- Urinary Excretion3
- Clerance145 ml/min/kg
- ToxicityThe adverse events reported in more tha 10% of patients treated with Capecitabine include: gastrointestinal: diarrhea, nausea, stomatitis, vomiting, abdominal pain; skin and subcutaneous tissue disorders: hand-foot syndrome; general disorders and Administration site conditions: fatigue, asthenia, lethargy;
- LD50 (rat)N/A
- LD50 (mouse)N/A